Product Partnering

Product Partnering is our major thrust area and to facilitate this process. We partner major pharmaceutical companies in India & abroad as a reliable and efficient contract manufacturer.

Articles from Deus Medical


Oxymetholone for the treatment of HIV-wasting

ANADROMED 50 (Oxymetholone) is an anabolic steroid, which is a man-made form of a hormone similar to testosterone. Oxymetholone appears to be very effective in countering wasting among HIV-positive patients taking highly active antiretroviral therapy (HAART).

The U.S. Centers for Disease Control and Prevention (CDC) classified HIV wasting as an AIDS-defining condition in 1987. The "wasting syndrome" is characterized by the following criteria: weight loss of at least 10% in the presence of diarrhea or chronic weakness and documented fever for at least 30 days that is not attributable to a concurrent condition other than HIV infection itself. Wasting (cachexia) should not be confused with simple weight loss. Wasting is the condition characterized by involuntary weight loss, meaning the loss of body size and mass, most notably lean muscle.

Numerous studies have been demonstrated a significant relationship between weight loss, mortality, and disease progression. Because, in addition to weight loss, depleted levels of body cell mass, which contains the metabolically active tissue, have been associated with increased risk of mortality in patients with HIV infection. Weight loss in HIV infection is characterized by the reduction of both fat and lean tissue. Such rapid weight loss has been associated with acute infections, whereas more gradual weight loss has been associated with malabsorptive disorders. Also, patients with HIV infection usually experience periods of weight stability and weight gain.

Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting was performed to find out if the Oxymetholone can be considered an effective anabolic steroid in eugonadal male and female patients with AIDS-associated wasting. Despite highly active antiretroviral therapy (HAART), chronic involuntary weight loss remains a very serious problem for HIV patients due to various alterations in energy metabolism and endocrine regulation. Previously, studies in HIV-positive men undergoing androgen replacement therapy or treatment with recombinant growth hormone (rGH) have shown partial restoration of lean body mass (LBM), but these treatments haven’t been sufficiently studied in eugonadal individuals.

The current trial of 89 HIV-positive eugonadal women and men with wasting syndrome, which was assigned either to the anabolic steroid Oxymetholone (50 mg bid or tid) or placebo for 16 weeks, was performed. Following characteristics were analyzed: body weight, bioimpedance measurements, quality of life parameters, and appetite.

Results of the trial outlined that the use of Oxymetholone led to a significant weight gain of 3.0 +/- 0.5 and 3.5 +/- 0.7 kg in the tid and bid groups, respectively (p <.05 for each treatment versus placebo), while individuals in the placebo group gained an average of 1.0 +/- 0.7 kg. Body cell mass (BCM) increased in the oxymetholone bid group (3.8 +/- 0.4 kg; p <.0001) and in the oxymetholone tid group (2.1 +/- 0.6 kg; p <.005). Significant improvements were noted in appetite and food intake, increased wellbeing, and reduced weakness by self-examination. The most important side effect was liver-associated toxicity. Overall, 43% of patients in the tid group, 25% of patients in the bid oxymetholone group, and 8% in the placebo group had a greater than 5 times baseline increase for ALT, AST, or gamma GT, while other adverse events were not increased over placebo.

As a conclusion, that’s must be said, that Oxymetholone can be considered an effective anabolic steroid in eugonadal male and female patients with AIDS-associated wasting. The bid (100 mg/day) regimen appeared to be equally effective to the tid (150 mg/day) regimen in terms of weight gain, LBM, and BCM and was associated with less liver toxicity.


The use of the non-selective androgen HALOMED 5 (Fluoxymesterone) in patients with metastatic breast cancer (MBC)

HALOMED 5 (Fluoxymesterone) is a synthetic androgen or male hormone, in its action, it is similar to testosterone. HALOMED 5 (Fluoxymesterone) is used to treat women with hormone-dependent breast cancer. It works by attaching itself to androgen receptors, what in turn, causes it to interact with the parts of the cell involved in the making of proteins. This process may cause an increase in the synthesis of some proteins or a decrease in the synthesis of others. These proteins have a variety of effects, including blocking the growth of some types of breast cancer cells. Finding and treating breast cancer in the early stages is extremely important, as this allows many women to be cured.

Metastatic breast cancer also referred to as metastases, advanced breast cancer, secondary tumours, secondaries or stage 4 breast cancer, is a stage of breast cancer where the disease has spread to another part of the body, most commonly the liver, brain, bones, or lungs. At this stage cancer cells can break away from the original tumor in the breast and travel to other parts of the body through the bloodstream or the lymphatic system, which serves as a large network of nodes and vessels that works to remove bacteria, viruses, and cellular waste products. The thing is, that breast cancer can return in another part of the body months or years after the original diagnosis and treatment.

There is no cure for metastatic breast cancer, this disease is not hopeless. Many patients continue to live long and productive lives with breast cancer in this stage. Although metastatic breast cancer is unlikely to be cured, there have been meaningful improvements in survival rate due to a wide variety of effective treatment options available, including endocrine therapy (ET) in the treatment of hormone-sensitive disease. ET alone or in combination with targeted agents can be a great help in fighting the disease. Also, new medicines are being tested every day. For this stage of breast cancer, treatment is often given for as long as the drug is helpful. If one treatment stops working, there is usually another one.

HALOMED 5 (Fluoxymesterone) is used for the treatment of metastatic breast cancer in menopausal women who have hormone receptor-positive tumors. The use of the non-selective androgen HALOMED 5 (Fluoxymesterone) in patients with metastatic breast cancer (MBC) reduced in the 1960s because of its adverse side effects. Although HALOMED 5 (Fluoxymesterone) has proved its efficacy against tamoxifen-resistant disease in clinical studies, today its role in cancer treatment is unclear. However, recent studies have shown that the androgen–androgen receptor (AR) complex acts as a suppressor of the estrogen receptor (ER)+ breast cancer. When Fluoxymesterone is used as a breast cancer treatment, this drug blocks the growth of tumor cells that are dependent on female hormones to grow. That is important to note, that HALOMED 5 (Fluoxymesterone) can be used only on female breast cancer patients who have reached menopause one to five years earlier, or as a result of surgery. HALOMED 5 (Fluoxymesterone) can be used in addition to other chemotherapeutic drugs, such as tamoxifen or cyclophosphamide, doxorubicin, and fluorouracil.


MASTERMED E 200 (Drostanolone Enanthate) as a potential treatment for breast cancer

MASTERMED E 200 (Drostanolone Enanthate) is an injectable anabolic steroid with powerful androgenic effect (AASs). Additionally, MASTERMED E 200 (Drostanolone Enanthate) and its esters derivatives can inhibit the production of estrogen. It is a DHT-derived steroid that can either have the long, slow-acting ester called ‘Propionate' or the short, faster-acting ester called ‘Enanthate’ attached to it, which controls the rate at which the steroid is released into the bloodstream. Propionate ester of Drostanolone is also used for the treatment of breast cancer, under the brand name of MASTERMED E 200 (Drostanolone Enanthate).

Currently, cancers are the second leading cause of death in the United States, and all across the world. According to the data from the World Health Organization (WHO), the prevalence of cancer is exceeding 6 million cases per year. Cancer cells have a high proliferation rate. They spread very rapidly in the living system, and are resistant against strong chemotherapeutics and DNA damaging agents. Breast cancer is the most commonly occurring cancer in women and the second most common cancer overall. There were over 2 million new cases in 2018 in 140 countries in 184 countries worldwide. It is a major cause of cancer-related death in females all across the world, now it represents one in four of all cancers in women. Globally, since 2008, worldwide breast cancer incidence has increased by more than 20 percent. Mortality has increased by 14 percent.

The medical community is now in search of selective and effective anti-cancer agents. Can anti-cancer steroids, such as MASTERMED E 200 (Drostanolone Enanthate), be used as a potential treatment for breast cancer?

MASTERMED E 200 (Drostanolone Enanthate) is an older anabolic steroid that was introduced in the last 1950s. In the 70s and 80s, MASTERMED E 200 (Drostanolone Enanthate) became very popular and is widely used as a potential therapeutic aid for the treatment of Breast Cancer in post-menopausal women. It is a treatment for breast cancer when operating isn’t a choice.


PRIMOMED 100 (Methenolone Enanthate) for the treatment of aplastic anemia

PRIMOMED 100 (Methenolone Enanthate) is a dihydrotestosterone based anabolic steroid. PRIMOMED 100 (Methenolone Enanthate) is utilized in the medical field to treat individuals suffering from conditions in which muscle wasting and severe weight loss is a symptom. PRIMOMED 100 (Methenolone Enanthate) is indicated for the treatment of aplastic anemia, breast cancer, and postmenopausal osteoporosis. Other uses also include: the drug can be used as an immunostimulant for individuals fighting infections, wasting conditions, an adjunct to countering the effects of prolonged corticosteroid therapy, and the treatment of osteoporosis as well as sarcopenia (the loss of muscle as correlated with aging).

In the case of aplastic anemia, patients suffering from this disease don’t have enough functioning red blood cells (RBCs). RBCs are the ones responsible for carrying oxygen. If the person is anemic, the body can’t transport oxygen efficiently and the person becomes tired and weak.

RBCs carry oxygen using a protein called hemoglobin, which is necessary for efficient oxygen transport. Hemoglobin tightly binds oxygen in areas with high oxygen and then releases it in areas that need oxygen. Also, it gives the red color to the blood. Hemoglobin contains iron, which is necessary for hemoglobin to bind oxygen. Mostly anemia arises from an iron deficiency. In such cases, these types of anemia are easily treatable.

That is different from aplastic anemia, which starts with a bone marrow problem and it is not caused by iron deficiency. Aplastic anemia is a very rare condition, which can be fatal if left untreated. Adult doses for the treatment of aplastic anemia are usually in a range of 1–3 mg/kg per day. Of course, like with any other steroid, adverse side effects sometimes can be present. These side effects include fluid and electrolyte retention, hypercalcemia, increased bone growth, and skeletal weight. In men patients, additional side priapism, azoospermia, hirsutism, male pattern baldness, acne, and oedema can also appear. In women patients, additional side effects include virilization, amenorrhoea, menstrual irregularities, suppressed lactation, and increased libido.

Although, PRIMOMED 100 (Methenolone Enanthate) is known to be mild in its negative side effects (it has also been utilized in children and infants to promote weight gain without any indications of ill effects or toxicity). However, in children, side effects may include premature closure of epiphyses, cessation of linear growth, and virilization symptoms.

In case of appearance of any of the following symptoms of aplastic anemia, that is advised to immediately see your doctor. In general, the symptoms of aplastic anemia are similar to general anemia. They include dizziness, excessive fatigue, sensitivity to cold temperatures, weakness, rapid heart rate, irritability, paleness, and shortness of breath. Low platelet counts can also cause nose bleeds, bleeding in the gums, the skin to bruise easily and rash with small pinpoints.


PROVIMED 25 (Mesterolone) for the Treatment of Male Infertility

PROVIMED 25 (Mesterolone) belongs to the group of medicines known as androgens, which work by supplementing your body's natural male sex hormones. Meaning, that PROVIMED 25 (Mesterolone) tablets are prescribed for men to treat disorders where the body does not make enough natural androgen. PROVIMED 25 (Mesterolone) is a new androgen used for Male infertility, Testosterone deficiency, and other conditions.

In general, hormonal treatment of male infertility has mainly involved the use of androgens and gonadotropins for disturbances in spermatogenesis. That is very important to note, that the treatment of male infertility depends upon the underlying cause, which includes:

  • Physical problems with the testicles
  • Blockages in the ducts that carry sperm
  • Hormone problems
  • A history of high fevers or mumps
  • Genetic disorders
  • Lifestyle or environmental factors

It is possible that Male Infertility shows no physical symptoms and still be present in a patient. Many infertile couples have more than one cause of infertility. About a third of the cases, infertility is because of a problem with the man. One-third of the time, it is a problem with the woman. That is necessary for a couple to see a doctor together. In some cases, a cause is never identified. It might take several tests to outline the cause of infertility. Usually, several months to years of treatment are necessary to achieve fertility.

During the treatment with PROVIMED 25 (Mesterolone), that is important to have regular blood tests and examinations of prostate and breasts. The reason is that the treatment may increase the rate of growth of some types of cancer.

A prospective randomized double-blind study was undertaken to determine the effect on male fertility after 6 months' treatment with the synthetic androgen PROVIMED 25 (Mesterolone) . The study was performed in seven centres and 248 infertile couples were recruited randomly. All couples were investigated according to the standardized WHO protocol--Investigation and Diagnosis of the Infertile Couple. During this investigation, 157 couples were selected in whom the male diagnosis was a primary idiopathic testicular failure or idiopathic low sperm motility; while the female partner had no visible cause for infertility or was under successful treatment for a minor endocrine problem. Men received either 150 or 75 mg Mesterolone daily or placebo. Results were assessed in terms of semen characteristics and the partner's pregnancy rate.

8 months after the study, pregnancy rates among all couples were 9 +/- 3% (+/- standard error), 12 +/- 4% in the placebo, and 16 +/- 4% in 75 and 150 mg PROVIMED 25 (Mesterolone) groups, respectively. Among 157 couples satisfying the strict eligibility criteria, the pregnancy rates were 11 +/- 5% in the placebo group, and 12 +/- 5% and 19 +/- 6%, in 75 and 150 mg PROVIMED 25 (Mesterolone) groups, respectively. There were no significant changes in semen quality during the study, apart from an increase in sperm concentration 3 months after the start of treatment. That is curious, but the increase was greatest among the placebo-treated group, although it did not differ significantly between treatment groups.